Treatment with the SIRT1 activity inhibitor triggered the anticancer effects of cisplatin and pemetrexed in human lung cancer cells, lung orthotopic tumors and a spontaneous in vivo model of KRAS<sup>Mut</sup> lung cancer. Here, KRAS is linked to lung cancer.